Schena F P, Cerullo G, Torres D D, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri G M, Amoroso A
Renal, Dialysis and Transplant Unit, Department of Emergency and Organ Transplant, University of Bari, Bari, Italy.
Contrib Nephrol. 2007;157:80-9. doi: 10.1159/000102308.
Idiopathic IgA Nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis worldwide. All races with the exception of Blacks and Indians are involved. Families with two or more relatives affected by IgAN may be observed in 15-20% of pedigrees of IgAN patients. Genome wide linkage study has been considered the most promising approach to identify IgAN susceptibility genes. Therefore, some European investigators constituted the European IgAN Consortium which was initially funded by the European Union. Data from linkage analysis studies, family association studies and case-control association studies are reported. To date, the Consortium has identified two loci (located on chromosomes 4q26-31 and 17q12-22), in addition to the previous study which described the first IgAN locus on chromosome 6q22-23. The functional mapping of genes involved in the disease proceeds from the identification of susceptibility loci identified by linkage analysis (step 1) to the isolation of candidate genes within gene disease-susceptibility loci, after obtaining information by microarray analysis carried out on peripheral leukocytes and renal tissue samples (step 2). Then, the process will proceed from the design of RNA interferenceagents against selected genes (step 3) to the application of systematically tested effect of RNA agents on functional cellular assay (step 4). The above combined high-throughput technologies will give information on the pathogenic mechanisms of IgAN. In addition, these data may indicate potential targets for screening, prevention and early diagnosis of the disease and more appropriate and effective treatment.
特发性IgA肾病(IgAN)是全球范围内经活检证实的最常见的肾小球肾炎。除黑人和印第安人外的所有种族均有发病。在15%至20%的IgAN患者家系中可观察到有两名或更多亲属患IgAN的家庭。全基因组连锁研究被认为是识别IgAN易感基因最有前景的方法。因此,一些欧洲研究人员组成了欧洲IgAN联盟,该联盟最初由欧盟资助。报告了连锁分析研究、家族关联研究和病例对照关联研究的数据。迄今为止,该联盟除了之前描述的位于6号染色体q22 - 23上的首个IgAN基因座外,还确定了两个基因座(位于4号染色体q26 - 31和17号染色体q12 - 22)。对参与该疾病的基因进行功能定位,首先通过连锁分析确定易感基因座(步骤1),然后在对外周血白细胞和肾组织样本进行微阵列分析获得信息后,分离疾病易感基因座内的候选基因(步骤2)。接着,该过程将从针对选定基因设计RNA干扰剂(步骤3)推进到在功能性细胞检测中系统测试RNA剂的作用效果(步骤4)。上述组合的高通量技术将提供有关IgAN致病机制的信息。此外,这些数据可能为该疾病的筛查、预防和早期诊断以及更合适有效的治疗指明潜在靶点。